Association between manganese superoxide dismutase promoter gene polymorphism and breast cancer survival

Breast Cancer Research

Table 3 Manganese superoxide dismutase -102 genotype: overall and recurrence-free survivals with radiation therapy

Genotype	Cases	Deaths	Hazard ratio minimally adjusted^a (95% confidence interval)	Hazard ratio fully adjusted^b (95% confidence interval)
Overall survival	150	33	P for trend = 0.67	P for trend = 0.91
CC	93	20	1 (reference)	1 (reference)
CT	51	11	0.97 (0.46–2.04)	0.74 (0.35–1.58)
TT	6	2	1.95 (0.45–8.49)	2.23 (0.46–10.79)
CC	93	20	1 (reference)	1 (reference)
CT + TT	57	13	1.05 (0.52–2.12)	0.82 (0.40–1.70)
Recurrence-free survival	145	40	P for trend = 0.14	P for trend = 0.03
CC	90	29	1 (reference)	1 (reference)
CT	50	10	0.57 (0.28–1.18)	0.40 (0.18–0.86)
TT	5	1	0.60 (0.08–4.47)	0.69 (0.09–5.46)
CC	90	29	1 (reference)	1 (reference)
CT + TT	55	11	0.57 (0.28–1.16)	0.42 (0.20–0.87)

CC, homozygous for the wild-type manganese superoxide dismutase gene; CT, heterozygous for the variant genotype; TT, homozygous for the variant genotype. ^aMinimally adjusted model: age. ^bFully adjusted model: age, stage with node status at diagnosis, race, estrogen receptor status, and progesterone receptor status.

ISSN: 1465-542X